Aim Retrospective analysis of disease clinical course with a purpose of defining potential prognostic parameters which are essential for optimal target therapy. Methods The study involved 29 patients with histologically confirmed lung adenocarcinoma and existing epidermal growth factor receptor (EGFR) mutations, which are treated by tyrosine kinase inhibitors (TKI). Results Allegations of a larger prevalence in women and non-smokers were found. The study confirmed dominance of mutations on exon 19 and exon 21. Usefulness of the treatment with erlotinib in terms of increasing survival time was evident. Median survival of patients in the survey sample was 14.5 months. Median survival in relation to gender or smoking status did not show statistical significance. Conclusion Considering obtained results, we have confirmed that patients with advanced lung adenocarcinoma and present mutations of epidermal growth factor receptor, who had been treated with first generation TKI, had median survival time of over a year.
Massarelli E, Johnson F, Erickson H, Wistuba I, Papadimitrakopoulou V. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer. 2013. p. 235–41.
2.
Hanna N, Johnson D, Termin S, Baker S, Jr, Brahmer J, et al. Systemic therapy for stage IV non-small-cell lung cancer. J Clin Oncol. American Society of Clinical Oncology; 2017. p. 3484–515.
3.
Russell P, Wainer Z, Wright G, Daniels M, Conron M, Williams R. Does lung adenocarcinoma subtype predict patients survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracis Society/European Respiratory Society International multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011. p. 1496–504.
4.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013. p. 11–30.
5.
Cancer Facts and Figures. American Cancer Society; 7AD.
6.
Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2014. p. 388–96.
7.
Saruwatari K, Ikemura S, Sekihara K, Kuwata T, Fujii S, Umemura S, et al. Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations. Lung Cancer. 2016. p. 7–14.
8.
Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005. p. 339–46.
9.
Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet. 2013. p. 26–31.
10.
Kraweczyk P, Ramlau R, Chorostowska-Wynimiko J, Powrozek T, Levandovska M, Limon J, et al. The efficacy of EGFR gene mutation testing in various samples from non small cell lung cancer patients: multicentre retrospective study. J Cancer Res Clin Oncol. 2015. p. 61–8.
11.
Lindeman N, Cagle P, Aisner D, Arcila M, Beasley M, Bernicker E, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018. p. 323–58.
12.
Cufer T, Knez L. Update on systemic therapy of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2014. p. 1189–203.
13.
Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Update overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013. p. 54–9.
14.
Roberts P, Stinchombe T. KRAS mutations: Should we test for it, and does it matter? J Clin Oncol. 2013. p. 1112–21.
15.
TNM Classification of Malignant Tumours. 7AD.
16.
Denholm R, Schuz J, Straif K. Is previous respiratory disease a risk factor for lung cancer? Am J Respir Crit Care Med. 2014. p. 549–59.
17.
Schabath M, Thompson Z, Gray J. Temporal trends in demographics and overall survival of nonsmall-cell lung cancer patients at Moffitt Cancer Center from 1986 to. Cancer Control. 2008. p. 51–6.
18.
Hébert J, Daguise V, Hurley D, Wilkerson R, Mosley C, Adams S, et al. Mapping cancer mortalityto-incidence ratios to illustrate racial and sex disparities in a high-risk population. Cancer. 2009. p. 2539–52.
19.
Philip T, Timothy C. Lung cancer genotype-based therapy and predictive biomarkers. Arch Pathol Lab Med. 2012. p. 1482–92.
20.
Haaland B, Tan P, De Castro G Jr, Lopes G. Meta-analysis of first-line therapies in advanced nonsmall-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol. 2014. p. 805–11.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
